Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy
The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Academia Brasileira de Neurologia - ABNEURO
2006
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2006000500001 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0004-282X2006000500001 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0004-282X20060005000012006-10-11Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsySilveira,Mariana Ribeiro Marcondes daMontenegro,Maria AugustaFranzon,Renata CristinaGuerreiro,Carlos A.M.Guerreiro,Marilisa M. clobazam focal epilepsy childhood The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.64 n.3b 20062006-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2006000500001en10.1590/S0004-282X2006000500001 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Silveira,Mariana Ribeiro Marcondes da Montenegro,Maria Augusta Franzon,Renata Cristina Guerreiro,Carlos A.M. Guerreiro,Marilisa M. |
spellingShingle |
Silveira,Mariana Ribeiro Marcondes da Montenegro,Maria Augusta Franzon,Renata Cristina Guerreiro,Carlos A.M. Guerreiro,Marilisa M. Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
author_facet |
Silveira,Mariana Ribeiro Marcondes da Montenegro,Maria Augusta Franzon,Renata Cristina Guerreiro,Carlos A.M. Guerreiro,Marilisa M. |
author_sort |
Silveira,Mariana Ribeiro Marcondes da |
title |
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
title_short |
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
title_full |
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
title_fullStr |
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
title_full_unstemmed |
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
title_sort |
effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy |
description |
The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures. |
publisher |
Academia Brasileira de Neurologia - ABNEURO |
publishDate |
2006 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2006000500001 |
work_keys_str_mv |
AT silveiramarianaribeiromarcondesda effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy AT montenegromariaaugusta effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy AT franzonrenatacristina effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy AT guerreirocarlosam effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy AT guerreiromarilisam effectivenessofclobazamasaddontherapyinchildrenwithrefractoryfocalepilepsy |
_version_ |
1756374347531943937 |